pharmaphorum18h
Biogen bags rights to epilepsy drug from Stoke in $550m deal
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
Earnings call transcript: Biogen Q4 2024 EPS beats estimates, stock drops
Biogen Inc. (NASDAQ:BIIB), currently valued at $19.15 billion by market capitalization, reported its earnings for the fourth ...
Biogen’s stock slides on soft guidance and a decline in sales of MS drugs
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...
Biogen's Options Frenzy: What You Need to Know
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...
Biogen price target lowered to $265 from $298 at Canaccord
Canaccord lowered the firm’s price target on Biogen (BIIB) to $265 from $298 and keeps a Buy rating on the shares. The firm noted the market ...
Biogen price target lowered to $245 from $281 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...
Nasdaq8d
Biogen's Options Frenzy: What You Need to Know
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Biogen's whale activity within a strike price range from $130.0 to $250.0 in the ...
Morningstar7d
Biogen's stock slides on soft guidance and a decline in sales of MS drugs
based Biogen had net income of $266.8 million ... The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid ...